Study of RP-3500 With Niraparib or Olaparib in Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the safety and tolerability of Niraparib or
Olaparib in combination with RP-3500, in patients with eligible advanced solid tumors,
determine the maximum tolerated dose (MTD) of RP-3500 in combination with Niraparib or
Olaparib, examine pharmacokinetics (PK) and assess anti-tumor activity.